The world of mental health is constantly evolving, with new treatments, challenges, and insights emerging all the time. Let's dive into some of the latest headlines from the psychiatry world.
First up, we saw a spike in Google searches for lorazepam, a benzodiazepine, following the recent season of the hit TV show "The White Lotus." This highlights the powerful influence of media on our understanding and perceptions of mental health medications.
Next, BrainsWay announced an FDA expansion for their Deep Transcranial Magnetic Stimulation system, now cleared for use as an adjunct therapy for adolescents aged 15 to 21 with major depression. This is a significant step forward, offering a new treatment option for a vulnerable age group.
In a promising development, a small trial showed that deep brain stimulation of specific brain areas resulted in a 50% response rate and a 35% remission rate in patients with treatment-resistant depression. This suggests that targeted brain stimulation could be a powerful tool for those who haven't found relief through other methods.
However, not all news is positive. The investigational glycine transporter 1 inhibitor iclepertin failed to improve cognition in adults with schizophrenia across three phase III trials. This is a setback, as it indicates that this potential treatment did not deliver the expected results.
And this is the part most people miss... Lady Gaga shared her experience with lithium while filming "A Star Is Born," including a subsequent psychotic break. This provides a raw, personal perspective on the impact of medication and mental health struggles, emphasizing the importance of open conversations and support.
Do those lamps designed to combat seasonal affective disorder actually work? Experts suggest they probably do, offering a simple, accessible way to manage seasonal depression.
But here's where it gets controversial... A meta-analysis revealed that GLP-1 receptor agonists, particularly semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda), helped reduce alcohol use and had positive effects on relapse and alcohol-related health issues. This opens up new avenues for treating alcohol use disorders.
In a small, open-label trial, microdosing LSD at home appeared safe and feasible for individuals with depression. While this is preliminary, it could lead to new ways of treating depression.
Veterans with post-traumatic headache showed a significantly higher risk of suicidal ideation and attempts compared to those with headache-free traumatic brain injury. This underscores the need for better mental health support for veterans.
Finally, a meta-analysis showed high rates of uptake (92.4%) and adherence (61.8%) to depression and anxiety apps. This indicates that digital mental health tools are becoming increasingly accepted and utilized.
What are your thoughts on these developments? Do you think the media's portrayal of mental health medications is accurate? Share your opinions in the comments below!
